RESEARCH ARTICLE 3641

Development 133, 3641-3650 (2006) doi:10.1242/dev.02540

The transcription factor ZBP-89 controls generation of the hematopoietic lineage in zebrafish and mouse embryonic stem cells
Xiangen Li, Jing-Wei Xiong, C. Simon Shelley, Heiyoung Park and M. Amin Arnaout*
Hematopoietic development is closely linked to that of blood vessels and the two processes are regulated in large part by transcription factors that control cell fate decisions and cellular differentiation. Both blood and blood vessels derive from a common progenitor, termed the hemangioblast, but the factor(s) specifying the development and differentiation of this stem cell population into the hematopoietic and vascular lineages remain ill defined. Here, we report that knockdown of the Krppel-like transcription factor ZBP-89 in zebrafish embryos results in a bloodless phenotype, caused by disruption of both primitive and definitive hematopoiesis, while leaving primary blood vessel formation intact. Injection of ZBP-89 mRNA into cloche zebrafish embryos, which lack both the hematopoietic and endothelial lineages, rescues hematopoiesis but not vasculogenesis. Injection of mRNA for Stem Cell Leukemia (SCL), a transcription factor that directs hemangioblast development into blood cell precursors, rescues the bloodless phenotype in ZBP-89 zebrafish morphants. Forced expression of ZBP-89 induces the expansion of hematopoietic progenitors in wildtype zebrafish and in mouse embryonic stem cell cultures but inhibits angiogenesis in vivo and in vitro. These findings establish a unique regulatory role for ZBP-89, positioned at the interface between early blood and blood vessel development.
KEY WORDS: Hematopoiesis, Angiogenesis, ZBP-89 gene, SCL/tal-1 gene, Stem cells

Nephrology Division, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. *Author for correspondence (e-mail: arnaout@receptor.mgh.harvard.edu) Accepted 18 July 2006

DEVELOPMENT

INTRODUCTION Vertebrate hematopoiesis occurs in two developmental waves: a short primitive wave, predominantly generating erythrocytes and primitive myeloid cells, and a denitive wave, producing long-term hematopoietic stem cells (Orkin and Zon, 2002). Hematopoietic stem cell (HSC) progenitors are believed to arise from bipotential fetal liver kinase-1+ (FLK1+; KDR Zebrash Information Network) mesoderm stem cells (Choi et al., 1998; Huber et al., 2004; Palis et al., 1999; Thompson et al., 1998), which also give rise to vascular progenitors. The genetic regulatory networks that control blood and blood vessel development have been extensively studied but the factors that regulate the generation of blood and blood vessels from FLK1+ hemangioblasts are incompletely understood. One such factor is the product of the cloche (clo) gene, which is essential for generating both the hematopoietic and vascular progenitors (KalevZylinska et al., 2002; Liao et al., 1998; Liao et al., 1997; Stainier et al., 1995; Thompson et al., 1998), but its nature remains to be dened. A second factor, SCL, is a basic helix-loop-helix transcription factor encoded by the scl/tal1 gene that has been shown to be essential in directing hematopoietic fate commitment from hemangioblasts (Mikkola et al., 2003; Porcher et al., 1996; Robb et al., 1996), as well as in embryonic angiogenesis (Patterson et al., 2005; Visvader et al., 1998). Hematopoietic and endothelial lineages can be produced in vitro from murine embryonic stem cell (ESC)-derived embryoid bodies (EBs), in a temporal pattern that recapitulates the development of these cell populations in vivo (Palis et al., 1999). Analysis of early EBs, between days 2.5 and 4 of ESC

differentiation, prior to hematopoietic and endothelial lineage commitment, reveals the presence of a transient mesodermderived FLK1+ SCL+ progenitor, or blast colony-forming cell (BL-CFC), which represents the in vitro equivalent of the yolk sac hemangioblast (Chung et al., 2002; DSouza et al., 2005; Fehling et al., 2003; Park et al., 2005). The expression of c-kit (kita Zebrash Information Network) in this population indicates a hematopoietic potential (Willey et al., 2006). ZBP-89 (ZFP148) is the prototype of a novel class of transcription factors, phylogenetically conserved in mammals, that contains a characteristic array of three N-terminal C2H2 Krppellike zinc ngers and a fourth C2HC variant zinc nger. It shares homology with members of the Krppel-like nger (KLF) protein family with three Krppel-like zinc ngers (Bray et al., 1991); however, ZBP-89 has a fourth zinc nger and all four are located in the N-terminal region, in contrast to the conserved C-terminal location of the zinc ngers in the KLF protein family (Kaczynski et al., 2003). The ZBP-89 gene is localized on chromosome 3q21, the site of breakpoints (Pekarsky et al., 1995) and translocations (Yamagata et al., 1997) in some cases of acute myeloid leukemia (Antona et al., 1998; Bernstein et al., 1986), but it is not clear whether any of these involve the ZBP-89 gene itself. In the only in vivo study to date, haploinsufficiency of ZBP-89 caused infertility in normally developed male mice that was due to the growth arrest and apoptosis of fetal germ cells (Takeuchi et al., 2003). We have previously shown that ZBP-89 represses expression of the myeloid differentiation marker CD11b in vitro (Park et al., 2003). To explore its role in hematopoiesis in vivo, we cloned the zebrash ortholog, analyzed its expression, and characterized the phenotype resulting from modulating its expression in zebrash embryos and murine EB cultures. Our ndings identify a crucial function of ZBP-89 in embryonic blood and endothelial cell development, and place it downstream of clo and upstream of scl in the genetic hierarchy of early hematopoiesis.

3642 RESEARCH ARTICLE

Development 133 (18)

the manufacturers instructions (Roche). Antisense riboprobes to gata1, scl, lmo2, c-myb, k1, i1a, Tie1, cdx4, tif1g (moonshine), gata2, runx1, pu.1, lplastin and mpo have been described previously (Ransom et al., 2004; Davidson et al., 2003; Kalev-Zylinska et al., 2002; Liao et al., 1998; Thompson et al., 1998; Lyons, 1998). DIG-labeled riboprobes were detected using alkaline phosphatase-conjugated anti-DIG antibodies (Roche), followed by detection of alkaline phosphatase activity using NBT/BCIP substrate (Roche).
DAF staining

MATERIALS AND METHODS

Fish strains and maintenance

Breeding zebrash were raised, maintained and staged as described (Westereld, 1993). The clochem39 zebrash mutant lines, gata1:EGFP and k1:EGFP transgenic shes have been described elsewhere (Cross et al., 2003; Long et al., 1997; Stainier et al., 1995).
Cloning of the zebrash zbp-89 full-length coding sequence

Zebrash zbp-89 was cloned by RT-PCR based on the sequence predicted from Sanger Centers zebrash genomic DNA sequence (Sanger Institute), using the human ZBP-89 protein sequence as bait. The zebrash zbp-89 full-length coding sequence was all contained in Contig #25012. The predicted exon/intron boundary was obtained using the website: genes.mit.edu/GENSCAN.html. A series of PCR primers was designed accordingly and nested RT-PCR reactions were performed using total RNA from 24 hpf zebrash embryos. A 1.3 kb cDNA encoding the N-terminal fragment of ZBP-89 was generated in rst-round RT-PCR with the primers F1 (5 -TGCTGGAGGACATGAATCCACCAG-3 ) and R1 (5 -TGGAGAGAGACTCTGGGACTGCTC-3 ). The gel-puried (Qiagen) fragment was used as template DNA in a nested PCR reaction using the enzymerestricted (underlined) primers EcoRI-F (5 -AAGAGAATTCATGAACATTGATGACAAGCTGG-3 ) and XbaI-R (5 -CTGCTCTAGAGCCTGCTG-3 ). The nested PCR products were cloned into the EcoRI-XbaIrestricted PSK+ vector (PSK-1.3-ZBP-89) and sequenced. The 1.1 kb encoding the C-terminal fragment of ZBP-89 was cloned by following a similar strategy. The rst round primers were F2 (5 -TCCCCACCTGGCAGCAGGCATCTTG-3 ) and R2 (5 -AGCTTTTGTTCAGCCAAAGGTTTG-3 ), and the nested PCR primers were XbaI-F (5 -CAGCAGGCTCTAGAGCAG-3 ) and NotI-R (5 -AAGAGCGGCCGCTCAGCCAAAGGTTTGGCT-3 ). The 1.1 kb C-terminal fragment was inserted into the PSK-1.3-ZBP-89 vector to reconstitute the cDNA encoding the full-length protein.
Morpholino oligonucleotide, mRNA and plasmid microinjection

Embryos (36 hpf) were stained with DAF (2,7-diaminouorene), which sensitively stains hemoglobin, as described (Weinstein et al., 1996). In brief, embryos were xed in 4% paraformaldehyde (PFA) for 2 hours, washed three times in PBS, then pre-incubated in the DAF staining solution [0.01% diaminouorene, 200 mM Tris (pH 7.0), 0.05% Tween 20] for 1 hour at room temperature in the dark. Hydrogen peroxide was added to a nal concentration of 0.3%, and the embryos were incubated for 5-20 minutes. Embryos were washed three times in PBS then photographed.
RT-PCR analysis of zbp-89 expression

Whole-mount in situ hybridization

A 2.4 kb EcoRI-NotI-restricted zebrash zbp-89 fragment was cloned into the pBS (K+) vector. Antisense mRNA was transcribed from the EcoRIlinearized plasmid using T3 polymerase, and sense mRNA was transcribed from the NotI-linearized plasmid using T7 polymerase as a control. RNA antisense probes were generated with UTP-digoxigenin (DIG), according to

DEVELOPMENT

Three morpholino antisense oligonucleotides (MO) targeting the zbp-89 transcript were obtained from Gene-Tools, LLC. One oligomer (atgMO, 5 -CCTCCAGCTTGTCATCAATGTTCAT-3 ) was designed to block translation of the mRNA, leading to knockdown of the protein. A second (spliceMO, 5 -GTCAAAATATTACCTGATGGCAATA-3 ) targeted an exon splice donor site in exon 8. A third MO contained a ve-nucleotide mismatch in atgMO (Mismatched atgMO, 5 -CCaCCtGCTTGTgATCAATcTTgAT-3 ; mismatched bases are in small letters). Each morpholino oligomer was diluted in 100 mmol/l KCl, 10 mmol/l HEPES, 0.1% Phenol Red (Sigma). Embryos were microinjected at the one- to twocell stage with 4 ng of the morpholino oligomer (in a volume of 2 nl). RTPCR analysis revealed the formation of an alternative splice product in spliceMO-injected embryos that was predominant at 24 hpf and encoded a 237 amino acid ZBP-89 protein terminating after the second zinc nger domain. The full-length human ZBP-89 cDNA was directionally cloned into the EcoRI and XhoI sites of pCS2+ for overexpression. Human ZBP-89 sense RNA and zebrash scl sense RNA (Gering et al., 1998) were transcribed from linearized pCS2+-ZBP-89 using the mMessenge mMachine Kit according to the manufacturers protocol (Ambion). clo/ mutant embryos for microinjection were obtained from heterozygous in-crosses, and 100 pg of ZBP-89 mRNA was injected into one- to two-cell embryos. The fulllength human ZBP-89 coding region was subcloned downstream of the zebrash k1 promoter (Cross et al., 2003), using EcoRI and NotI sites, to generate the k1-ZBP-89 plasmid. For morpholino rescue experiments, 300 pg of RNA or 4 ng of the linearized k1-ZBP89 plasmid DNA were injected into one- to two-cell embryos immediately following the morpholino injection.

A single wild-type (WT) and a clo/ mutant zebrash embryo were harvested at the 18 hpf stage, rinsed twice with PBS and transferred into an RNase-Free tube containing 100 l Trizol RNA solution. Total RNA was extracted according to the manufacturers instructions (Ambion). Total RNA (4 l) was used as a template for cDNA synthesis, following the protocol from the Applied Biosystems manual. Two microliters from a total of 50 l cDNA were used for regular RT-PCR with the zebrash ZBP-89 forward (5 -GAAAAGCCTTTCCAGTGCAATCA-3 ) and reverse (5 -ATCTTTGACAGCTGTTTCTGCAC-3 ) primers. Mouse ZBP-89 expression in sorted cells from the FLK+SCL+, FLKSCL+ and FLK+SCL population was carried out as follows: 1 105 cells from each subset were collected, total RNA extracted and cDNA synthesized as described above. RT-PCR was performed using the mouse ZBP-89 forward (5 -GAGATTTCCTTCAGCGTTTAC-3 ) and reverse (5 TTTGGAAGGGTCTGGTTGTC-3 ) primers.
TUNEL assay

Zebrash embryos were staged and xed as for in situ hybridization and stored in methanol. After rehydration, embryos were permeabilized by proteinase K digestion, re-xed in buffered 4% PFA and washed in PBT. Apoptosis was detected in embryos by terminal transferase dUTP nick-end labeling (TUNEL), according to the manufacturers protocols (In Situ Cell Death Detection Kit: POD, Roche). The staining pattern was observed using light microscopy.
Real-time PCR

One million FLK1+ mesoderm stem cells were dissociated from EBs at different time points, rinsed twice with PBS and transferred into an RNasefree tube containing 100 l Trizol RNA solution. Total RNA isolation and cDNA synthesis were carried out as described earlier. Two microliters from a total of 50 l cDNA were used for real-time PCR, which was performed according to the manufacturers instructions (Stratagene). The ZBP-89 realtime PCR primers were: forward primer (ZBP-89RF1), 5 -CGGCATAGACGAAATGCAGTC-3 ; and reverse primer (ZBP-89RR1), 5 CCTGGTGAGGCAAACTTCGAT-3 . The internal control primers were: GAPDHF, 5 -TGACCACAGTCCATGCCATC-3 ; and GAPDHR, 5 GACGGACACATTGGGGGTTAG-3 .
ESC culture, differentiation and colony assays

J1 ES cells were maintained as described (Wang et al., 2004). Scl:hCD4 mouse ES cells (kindly provided by Dr K. Choi at the University of Washington, St Louis) (Chung et al., 2002) were generated by knock-in of the non-functional human CD4 receptor into the SCL locus, thus allowing quantitative counting of SCL+ cells by FACS analysis using the anti-hCD4 monoclonal antibody. Mouse ESC clones D5 and E1 that stably overexpress ZBP-89, and a control stable ES cell line, were generated by transfecting the linearized plasmid encoding mouse ZBP-89 under control of the -actin promoter (for the D5 and E1 ESCs) or the vector alone (control ESC), followed by selection in neomycin. The resulting ES cell lines were

ZBP-89 regulates hematopoiesis and angiogenesis

maintained on the mouse feeder cell line SNL in ES medium containing Dulbeccos modied Eagle medium (DMEM), 10 ng/ml mouse leukemia inhibitory factor (mLIF; Chemicon International, Temecula, CA), 15% fetal calf serum (FCS; HyClone, Logan, UT), 1 mM sodium pyruvate, 2 mM glutamine, 0.1 mM nonessential acid, 100 M monothioglycerol (MTG, Sigma, St Louis, MO), 50 U/ml penicillin and 50 g/ml streptomycin. ESCs were cultured to about 50% conuence on gelatin-coated plates prior to EB induction. Differentiation of ESCs into EBs and colony assays were carried out as described (Wang et al., 2004). Briey, EBs were generated in either liquid or 1% methylcellulose cultures (1 104 ESCs per 35-mm Petri dish) in ESC differentiation medium containing Iscove Modied Dulbeccos medium (IMDM), 15% FCS, 2 mM glutamine, 450 M MTG, 50 g/ml ascorbic acid and 20% BIT [1% bovine serum albumin (BSA), 10 g/ml insulin and 200 g/ml transferrin (StemCell Technologies)]. BL-CFCs were counted from EBs at 4 days of culture. To generate blast colonies from hemangioblasts, 1 104 EBs/ml were replated on 35-mm petri dishes in 1% methylcellulose in the presence of IMDM, 2 mM glutamine, 450 M MTG, 25 g/ml ascorbic acid, 20% BIT, 5 ng/ml human vascular endothelial growth factor (hVEGF), 50 ng/ml SCF, 10 ng/ml human broblast growth factor 2 (hFGF2), and 2 U/ml human erythropoietin (hEPO). BL-CFCs can be recognized as loose clusters of cells after 4 days of culture. Primitive erythroid progenitors were obtained from day 6 EBs. Denitive myeloid progenitors were obtained from day 10-12 EBs in 1% methylcellulose matrix. Hematopoietic colonies were counted 7-10 days after replating. For vascular-like EB culture, EBs were initially generated in 1% methylcellulose culture for 11 days, then transferred into collagen matrix for 3 days before being examined.
Immunostaining, ow cytometric analysis and sorting

RESEARCH ARTICLE 3643

the head mesenchyme and the intermediate cell mass (ICM, equivalent to the yolk sac in mammals) of 24-hour postfertilization (hpf) zebrash embryos (Fig. 1A-C), an expression pattern resembling that of scl (Liao et al., 1998). We used antisense morpholinos (MOs) targeting the translation start site (atgMO) or the splice donor site (spliceMO) in exon 8 in zbp-89, the latter of which causes a splicing defect, to knockdown expression of this gene in developing zebrash embryos. No blood cells were observed either within or outside of the vasculature in either atgMO- or spliceMO-injected live 48 hpf embryos (Fig. 1D-G; see also Movies 1 and 2 in the supplementary material), although all embryos displayed a beating heart. Over time, pericardial edema developed in MO-injected embryos, presumably because of the absence of blood circulation, and the morphants began to exhibit axis deformities, with the vast majority dying before 4 days post fertilization (dpf). Zebrash one- to two-cell embryos injected with an MO containing ve mismatches in atgMO (mismatched atgMO) developed normally (Fig. 1D,E). Subsequent analyses were carried out in the atgMO-generated morphants. The bloodless phenotype caused by the depletion of ZBP-89 was rescued by co-injecting atgMO with wild-type human ZBP-89 mRNA into wild-type embryos (data not shown), or with a plasmid in which ZBP-89 is expressed under the control of the k1 promoter into transgenic Tg (gata1:GFP) embryos (Fig. 1H-J). zbp-89-depleted zebrash embryos fail to develop primitive or denitive blood In zebrash, primitive hematopoiesis arises from two regions of the lateral mesoderm: the anterior lateral mesoderm located rostrally in the head region that gives rise to the myeloid lineage, and the posterior lateral mesoderm, which forms the ICM (the equivalent of the extraembryonic mammalian yolk sac blood island) just ventral to the notochord, where erythroid development takes place (AlAdhami and Kunz, 1977; Fouquet et al., 1997; Gering et al., 1998; Herbomel et al., 1999). Expression of the early hematopoiesis markers scl, lmo2 and gata2 (Liao et al., 1998) was reduced in 1224 hpf embryos depleted of zbp-89 (Fig. 1L,N,P; data not shown) when compared with controls (Fig. 1K,M,O). This loss was not caused by defects in mesoderm conversion into blood and blood vessel precursors, as reected by the normal expression of the caudal hox-related gene cdx4 (Davidson et al., 2003) (Fig. 1Q,R). Wholemount TUNEL staining of 22 hpf zbp-89 morphants did not reveal a signicant increase in the apoptosis of cells in the embryonic blood island and tail bud region when compared with wild-type embryos (data not shown), suggesting that ZBP-89 may be required for fate specication rather than survival of early hematopoietic precursors. Expression of the primitive erythroid markers gata1 and tif1g (moonshine) in the ICM (Fig. 2A,C) (Ransom et al., 2004) was lost almost entirely in zbp-89 morphants (Fig. 2B,D, respectively). However, expression of tif1g in the central nervous system was unaffected (Fig. 2C,D), reecting the specicity of the atgMOinduced defects for regions of active hematopoiesis. Expression of the primitive myeloid lineage markers pu.1, mpo and l-plastin (Fig. 2E,G,I) was also markedly downregulated in 24 hpf zbp-89 morphants (Fig. 2F,H,J). Denitive hematopoiesis in zebrash embryos occurs by 32 hpf in the ventral wall of the dorsal aorta, a region equivalent to the mammalian aorta-gonad-mesonephros (AGM) region (Burns et al., 2002; Kalev-Zylinska et al., 2002). We examined expression of the denitive hematopoiesis markers runx1 and c-myb, ablation of either one of which results in a complete absence of denitive hematopoiesis (Burns et al., 2002; Mucenski et al., 1991; Okuda

Single-cell suspensions were prepared from EBs cultured for different time periods by trypsinization for 2 minutes at 37C and then passing through a 21-gauge needle. Cells were immunostained (15 minutes, 4C in PBS/0.1% BSA buffer) with phycoerythrin (PE)- or allophycocyanin (APC)-rat antimouse monoclonal antibodies against c-KIT (APC), FLK1 (PE), SCA1 (PE), CD45 (FITC), VE-Cadherin, CD31 (PE) (PharMingen, Becton, San Diego, CA), or, in the case of Scl-hCD4 ESCs, with an additional biotinylated mouse monoclonal antibody to human CD4 (CALTAG), followed by streptavidin-APC (Sav-APC; Pharmingen). Cells stained with anti-VE-cadherin were visualized using a secondary PE-labeled goat antirat IgG. Cells were then analyzed using FACS Caliber, or sorted using FACS MoFlo (Becton Dickinson).
Western blotting

EBs were lysed with RIPA buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl (TBS), 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, freshly protease inhibitor cocktail (Roche)] for 30 minutes on ice then spun for 10 minutes at 4472 g. Samples were loaded onto 7.5% SDS-polyacrylamide gels together with molecular weight markers (Invitrogen), and transferred to nitrocellulose membrane. The blots were incubated with goat polyclonal IgG antibody to the conserved C terminus of human ZBP-89 (Santa Cruz; diluted 1:200 in TBS containing 0.05% Tween-20) overnight and washed extensively. After incubating with a donkey anti-goat IgG-horseradish peroxidase (HRP)-conjugated secondary antibody (Dako; diluted 1:2000) at room temperature for 1 hour, the blots were visualized using the ECL kit (BioRad), according to the manufacturers instructions. A mouse monoclonal anti- -actin antibody (Sigma) at a dilution of 1:500 was used to document equal loading per lane.

RESULTS Knockdown of ZBP-89 produces a bloodless phenotype in zebrash embryos To explore its role in hematopoiesis in vivo, we cloned the zebrash ortholog of ZBP-89 (see Fig. S1 in the supplementary material). Zebrash ZBP-89 shares a 74.1% similarity and 61.8% amino acid identity with human ZBP-89. Whole-mount in situ hybridization showed that zbp-89 is expressed in the posterior lateral mesoderm,

DEVELOPMENT

3644 RESEARCH ARTICLE

Development 133 (18)

Fig. 1. Expression prole of zbp-89 in wild-type zebrash embryos and the phenotype of zbp-89 morphants. (A-C) Tissue expression of zbp-89 by whole-mount in situ hybridization of 12 hpf (A), 18 hpf (B) and 24 hpf (C) embryos. Lateral views, dorsal upward, anterior to the left are shown. By 12 hpf (A), zbp-89 is expressed in the anterior (arrowhead) and posterior (arrow) lateral plate mesoderm. At 18 hpf (B), it is strongly expressed in the anterior ICM (arrow) and the brain region (arrowhead). At 24 hpf (C), expression in the anterior ICM (arrow) and the wedge region of the anterior ICM (short arrow) is seen together with expression in the brain (arrowhead). No signal was detected with the sense probe (not shown). (D-G) Loss of ZBP-89 results in a bloodless phenotype. DAF staining of 48 hpf whole-mount zebrash embryos. Blood (arrows) is present in the representative control (mismatch atgMO; D,E) but not in atgMO-injected (F,G) embryos (different embryos are shown in F and G). The bloodless phenotype was present in 78% and 62% of the 100-115 embryos injected at the one- to two-cell stage with either ZBP-89 atgMO or spliceMO, respectively. All views are lateral with anterior left and dorsal top. (H-J). Rescue of zbp-89 morphants by tissue-specic expression of human ZBP-89 under control of the k1 promoter. Gata1-driven GFP in 22 hpf transgenic (gata1:EGFP) zebrash embryos that were untreated (H), injected with atgMO only (I) or injected with atgMO plus k1-ZBP-89 plasmid (J) at the one- to two-cell stage. Single 22 hpf embryos were examined under a uorescent microscope revealing gata1 expression (red arrows) in the ICM of the untreated (H) and ZBP-89-rescued (J), but not in atgMO onlyinjected (I), embryos. (K-R) Effect of ZBP-89 knockdown on expression of early hematopoiesis markers. Whole-mount in situ hybridization in wildtype (WT; K,M,O,Q) and ZBP-89-depleted (L,N,P,R) 24 hpf embryos. Embryos were hybridized with digoxigenin-labeled RNA probes for scl (K,L), lmo2 (M,N) and gata2 (O,P). In wild type, scl is expressed in the anterior ICM (K, arrow), posterior ICM (arrowhead in K) and the wedge region of anterior the ICM (K, short arrow). Only minimal expression remains in the wedge region and the posterior ICM in the zbp-89 morphants (L). Lmo2 (M) and gata2 (O) display a similar expression pattern to scl in wild-type embryos, and expression of both is markedly reduced in the ICM of zbp-89 morphants (N and P, respectively). Gata2 is also expressed in the brain and spinal ganglia (short arrows in O,P); its expression at these sites is somewhat reduced by the loss of ZBP-89. (Q,R) Expression of cdx4 in the posterior ICM of 24 hpf wild type (Q) and zbp-89 morphants (R). cdx4 expression is not affected by the loss of ZBP-89.

et al., 1996). Expression of runx1 and c-myb was reduced by depletion of ZBP-89 in 24 hpf and 48 hpf zebrash embryos (Fig. 2K-R). This was particularly evident in the stem cell population associated with the dorsal aorta; the few cells that continued to express these markers were mostly conned to the posterior-most portion of the ICM. Thus, ZBP-89 depletion phenocopies the defects in primitive and denitive hematopoiesis seen in scl null mice (Porcher et al., 1996; Robb et al., 1996) and in scl zebrash morphants (Patterson et al., 2005). Expression of i1a and k1, which are indicative of primary blood vessel formation, was minimally affected by the loss of ZBP-89 in 18-20 hpf embryos (Fig. 2S,T; data not shown). ZBP-89 acts downstream of clo but upstream of scl To position ZBP-89 in the regulatory gene cascade leading to blood formation, we injected human ZBP-89 mRNA into one- to two-cell stage embryos collected from the clofv087b mapping cross. The injected embryos were xed at 3 dpf and stained with DAF, and those with positive DAF-staining were genotyped with the SSR marker z1496, which is very tightly linked to clofv087b (Fig. 3). Rescue of the hematopoietic program, detected by DAF staining, was observed in homozygous clo mutant embryos (Fig. 3E,F), indicating that ZBP-89 overexpression can rescue

hematopoiesis in the complete absence of clo function. This nding was also conrmed by overexpressing ZBP-89 in embryos from fv087b+/ clo Tg (gata1:GFP) crosses. As shown in Fig. 3H, this treatment rescued the GATA1+ cell population in the anterior ICM. To assess whether forced expression of ZBP-89 also reconstitutes blood vessel formation, we used a transgenic zebrash line, Tg (k1:EGFP), in which the k1 promoter directs the expression of EGFP (Cross et al., 2003). Flk1:EGFP is expressed in the blood vasculature of wild-type embryos (Fig. 3I), but is not expressed in clo embryos from fv087b+/:Tg (k1:EGFP) crosses (Fig. 3J). Injection of ZBP-89 mRNA into one-cell stage embryos from such crosses did not rescue k1 expression (Fig. 3K). Thus, ZBP-89 also acts functionally downstream of clo, but, in contrast to SCL, is able to rescue the hematopoietic but not the vascular lineage. We next evaluated the ZBP-89 transcript levels in clo mutants by RT-PCR. As shown in Fig. 3L, ZBP-89 mRNA was signicantly reduced in clo null mutant embryos when compared with wild-type embryos, which is consistent with the above functional data. To evaluate the functional relationship of ZBP-89 with SCL, scl RNA was co-injected with atgMO into one- to two-stage transgenic Tg (gata1:EGFP) zebrash embryos, where EGFP is

DEVELOPMENT

ZBP-89 regulates hematopoiesis and angiogenesis

RESEARCH ARTICLE 3645

Fig. 2. Expression of hematopoietic and vascular markers in wild type and zbp-89 morphants. (A-R) Expression of primitive erythroid (A-D), primitive myeloid (E-J) and denitive hematopoietic markers (KR). Normal expression (arrows) of the primitive erythroid genes gata1 (A) and tif1g (C) in the anterior ICM of wild-type embryos is almost completely lost in zbp-89 morphants (B,D, respectively). Expression of tif1g in neural tissue (arrowheads) is not affected. Expression of the primitive myeloid markers pu.1, mpo and l-plastin in wild type (E,G,I) and in zbp-89 morphants (F,H,J). The normal expression of pu.1 in primitive macrophages in the anterior ICM (arrow) in 24 hpf embryos (E) is markedly reduced by depletion of ZBP-89 (F). Its expression is also reduced in 20 hpf embryos in the head, rostral blood islands and ICM (not shown). mpo (G) and l-plastin (I) are normally expressed in the ICM of 24 hpf embryos (arrows) and in the anterior yolk region (l-plastin). Both markers are severely reduced by the loss of ZBP-89 (H,J, respectively). (K-R) Expression of the denitive hematopoietic markers runx1 and c-myb. Expression of runx1 begins in the ICM (K, arrows) at 24 hpf and is well developed in the ventral dorsal aorta at 48 hpf (M, arrows). Loss of ZBP-89 markedly reduces expression of runx1 in 24 hpf (L) and 48 hpf (N) embryos. c-myb is normally expressed in the ICM of wild-type embryos at 24 hpf (O, arrows). In 48 hpf embryos, cells expressing c-myb are found scattered along the ventral wall of the dorsal aorta (Q, arrows), within the rst progenitors of denitive hematopoiesis. c-myb expression is signicantly reduced in zbp-89 morphants in both 24 and 48 hpf embryos (P,R). Non-hematopoietic expression of runx1 (K,L) and c-myb (O,P) in neural tissue (arrowheads) was not affected by the loss of ZBP-89. (S,T) k1 expression in 20 hpf wild type and in zbp-89 morphants. k1 is normally expressed in cells located in two strips of the anterior lateral mesoderm (short arrows), and in the forming anterior (arrows) and posterior (arrowheads) ICM (S). This expression was not affected by the loss of ZBP-89 (T). All views are lateral with anterior left and dorsal top.

Ectopic expression of ZBP-89 in wild-type zebrash embryos expands the hematopoietic markers but impairs vascular remodeling Forced expression of ZBP-89 in wild-type zebrash embryos caused signicant expansion of the early hematopoietic markers scl, lmo2 and gata1 (Fig. 5B,D,F). However, expression levels of the wt1 and pax2.1 markers of the pronephros and pronephric duct, respectively (Gering et al., 2003), were unchanged (data not shown), suggesting that ectopic ZBP-89 expression did not change the fates of kidney mesoderm in the early lateral mesoderm. ZBP-89 overexpression induced a simultaneous reduction in k1 (Fig. 5H,L) and tie1 (Fig. 5J) expression in the intersomitic and axial blood vessels in 24 hpf embryos when compared with control (Fig. 5G,I,K). Expression prole of ZBP-89 in ESCs, hemangioblasts, and hematopoietic and angioblast progenitors To assess whether ZBP-89 is also crucial for hematopoietic development in mammals, we analyzed the expression of ZBP-89 in mouse embryonic stem cells (ESCs) undergoing differentiation into hematopoietic stem cells, and determined the consequences of its stable overexpression on hematopoietic and vascular development in vitro. The ZBP-89 transcript was not detected in undifferentiated ESCs but was rapidly induced in early (day 1) EBs, peaking in day 2 EBs then declining afterwards (Fig. 6A). Under similar conditions, expression of the early hematopoietic markers runx1, scl and gata1 begins at or after day 3 of culture (Lacaud et al., 2002), suggesting that in the mouse, as in zebrash, ZBP-89 acts upstream of these factors. The ZBP-89 protein was prominently expressed in day 3

under control of the gata1 promoter, a line that strictly labels erythrocytes (Long et al., 1997). We found that scl RNA rescued GATA1 expression in 22 hpf embryos, as well as pericardial edema and circulating blood in 48 hpf embryos (Fig. 4), and axial deformities in 3 dpf embryos (not shown). Thus, ZBP-89 acts upstream of scl in the transcriptional hierarchy of early hematopoiesis.

DEVELOPMENT

3646 RESEARCH ARTICLE

Development 133 (18)

Fig. 3. ZBP-89 rescues the hematopoietic but not the vascular phenotype in clo/ mutant zebrash embryos. (A,B) Wild-type whole-mount 3 dpf embryos stained with DAF and examined at 4 (A) and 10 (B) magnication, showing blood cells in the heart (red arrow), the dorsal aorta (arrow, B) and the posterior cardinal vein (arrowhead, B). (C,D) Clo/ embryo examined at at 4 (C) and 10 (D) magnication. No extravascular or circulating blood is seen. Red arrow in C indicates the dilated bloodless heart. (E,F) ZBP-89 sense RNA injected into clo/ embryos, shown at two different magnications. Blood formation in the trunk is evident (arrow in F), but the heart chamber remains dilated and devoid of erythrocytes (E), consistent with the absence of blood vessels. (G,H) Gata1-driven GFP in clo/ 48 hpf embryos transgenic (Tg) for gata-1:EGFP, before (G) and after (H) overexpression of ZBP89. Gata1 is found in the GFP-labeled erythroid lineage (arrow in H) in the anterior ICM of clo/ embryos overexpressing ZBP-89. (I-K) Tg (Flk1:EGFP) 48 hpf embryos showing uorescence in the axial (arrow in I) and intersomitic (short arrow in I) blood vessels; uorescence in the yolk extension is nonspecic. (J,K) k1-driven GFP in clo/ 48 hpf embryos transgenic for k1:EGFP before (J) and after (K) overexpression of ZBP-89. Arrows show a lack of blood vessel formation in both cases. (L) ZBP-89 expression prole in two different 18 hpf wild-type (WT1 and WT2) and clo/ (clo/1 and clo/2) embryos, assessed using RT-PCR. GAPDH expression was examined simultaneously as a reference.

EB-derived FLK1+ mesoderm precursors (Fig. 6A, inset), and its transcript was also present in FLK1+SCL+ hemangioblasts (BLCFC), FLK1SCL+ hematopoietic progenitors and in FLK1+SCL angioblasts derived from day 4 EBs (see Fig. S2 in the supplementary material). Overexpression of ZBP-89 in mouse ESCs leads to increased hematopoiesis but reduced sprouting angiogenesis We evaluated the role of ZBP-89 in hematopoietic and endothelial lineage commitment using the mouse ES cell in vitro differentiation system. Stable ectopic expression of ZBP-89 in ESC/EBs led to a

signicant increase in the hemangioblast (blast colony forming cell, BL-CFC) population (Fig. 6B). Stable overexpression of ZBP-89 in ESC/EBs also induced a 5-fold increase in the number of SCA1+/c-KIT+ hematopoietic progenitors in 3 day and 4 day EB cultures (not shown), a 2-fold expansion of primitive erythroid colonies (BFU-Es) (Fig. 6B), denitive erythrocyte (CFU-E), macrophage (CFU-M), granulocyte-macrophage-megakaryocyte (CFU-GEMM) and granulocyte-macrophage (CFU-GM) colonies (Kennedy et al., 1997) (Fig. 6C), and a 3-fold increase in the number of the cell population expressing the hematopoietic marker CD45 (Fig. 6D). By contrast, formation of the vascular plexus (Feraud et al., 2001) by the cultured ZBP-89-overexpressing EBs
Fig. 4. Rescue of zbp-89 morphants by zebrash scl sense RNA. (A-F) Gata1-driven GFP in 22 hpf transgenic (gata1:EGFP) zebrash embryos that were untreated (A,D), injected with atgMO only (B,E), or injected with atgMO plus scl RNA (C,F) at the one- to two-cell stage. (A-C) Single 22 hpf embryos examined under a uorescent microscope revealing gata1 expression (red arrows) in the ICM of the untreated (A) and scl-rescued (C) embryos, but not in the atgMO only-injected (B) embryos. (D-F) Bright-eld low magnication images of the respective untreated and treated Tg gata1:EGFP embryos at 48 hpf. Short arrows in E point to pericardial edema in the zbp-89 morphants.

DEVELOPMENT

ZBP-89 regulates hematopoiesis and angiogenesis

RESEARCH ARTICLE 3647

Fig. 5. Effect of forced expression of ZBP-89 on hematopoietic and vascular development in zebrash embryos. (A-J) Wild type (A,C,E,G,I) and ZBP-89-overexpressing (B,D,F,H,J) 18 hpf (A-F) or 24 hpf (G-J) zebrash embryos. In situ hybridization of wild-type embryos overexpressing ZBP-89 reveals a marked increase in the expression of scl (B), lmo2 (D) and gata1 (F), but a marked reduction in intersomitic expression of the endothelial markers k1 (H) and tie1 (J), when compared with the respective untreated wild-type embryos (A,C,E,G,I), (K,L) Wild-type (K) and ZBP-89-overexpressing (L) Tg (k1:EGFP) zebrash embryos examined at 24 hpf. Overexpression of ZBP-89 caused a signicant reduction in k1 expression in the axial (arrows), brain (short arrow) and intersomitic (arrowheads) blood vessels when compared with the control embryo.

Fig. 6. Expression prole of ZBP-89 and effects of its overexpression on hematopoiesis in mouse EB cultures. (A) ZBP-89 expression prole in undifferentiated ESCs and differentiating EBs quantied with real-time PCR. Numbers indicate the day of differentiation. Results represent means.d. of three independent experiments. Inset, western blot analysis showing induction of the ZBP-89 protein mainly in FLK1+ mesoderm precursors in day 3 EBs. Lane 1, positive control; lane 2, uninduced ESCs; lane 3, day 3 FLK1 mesodermal cells; lane 4, FLK1+ mesoderm precursors. Equivalent amounts of cell lysate were loaded per lane as reected by the actin signal. (B) Histograms showing the number of blasts (BL-CFCs), secondary EBs (2EBs) and primitive erythroid (BFU-Es) colonies generated from control, D5 and E1 clones (bars represent the mean number of coloniess.d. from two independent experiments). (C) Histograms (means.d., n=3) showing the numbers of denitive erythroid (CFU-E), macrophage (CFU-M), granulocyte-macrophagemegakaryocyte (CFU-GEMM) and granulocyte-macrophage (CFUGM) colonies. *P<0.01; **P<0.001 (paired t-test). (D) Flow cytometric analysis of a single-cell suspension from E1-derived EBs (see Materials and methods) stained with FITC-labeled rat antimouse CD45 monoclonal antibody. ZBP-89 overexpression signicantly increased the number of CD45+ hematopoietic progenitors.

DEVELOPMENT

3648 RESEARCH ARTICLE

Development 133 (18)

Fig. 7. Ectopic expression of ZBP-89 impairs angiogenesis in mouse EB cultures. (A) Primary day 11 EBs were dissociated and cultured in collagen matrix with growth factors for endothelial cell differentiation for four days. Histograms (means.d., n=3) show the number of primary day 11 EBs with 0, <5 or >5 branching vessels/EB derived from the D5 and E1 clones, compared with the control. *P<0.01; **P<0.001; NS, not signicant. (B) Representative images of control-, E1- or D5derived sprouting EB colonies. The reduction in the branching vessels (arrows in controls) in EBs derived from overexpressing ZBP-89 clones E1 and D5 is also clearly reected by the compactness of the respective colonies; fewer branches are produced compared with the controls. (C,D) Flow cytometric analysis of a single-cell suspension of EBs overexpressing ZBP-89 and stained with PE-labeled anti-CD31 (day 6 culture) or anti-VECadherin (day 7 and day 10 cultures) antibodies. ZBP-89 overexpression signicantly reduced the number of CD31+ and VE-Cadherin+ angioblasts (similar results were obtained in two other independent experiments).

was signicantly reduced (Fig. 7A,B), as was the number of the CD31+ (Fig. 7C) and VE-Cadherin+ (Fig. 7D) endothelial cell populations. DISCUSSION A major nding in this report is that the Krpple-like zinc nger transcription factor ZBP-89 is essential for blood formation in zebrash embryos and in vitro from differentiating mouse ESCs. zbp-89 depletion in zebrash impairs expression of the early hematopoietic genes scl, gata2 and lmo2, the primitive erythropoietic genes gata1 and tif1g (moonshine), the primitive myeloid genes pu.1, mpo and l-plastin, and the denitive hematopoietic genes runx1 and c-myb. Forced expression of ZBP89 in ESCs expanded the hematopoietic cell lineages. We place ZBP-89 upstream of scl and downstream of clo in controlling blood formation in zebrash on the basis of the following ndings. First, the bloodless phenotype in zbp-89 morphants is rescued by scl RNA. Second, upregulation and depletion of zbp-89 lead, respectively, to overexpression or loss of scl expression in zebrash embryos. This nding, together with the similar expression proles of both genes in zebrash and their co-expression in hematopoietic progenitors, suggests that SCL may be a direct target of ZBP-89. Third, the zbp89 transcript is reduced in clo/ mutants and zbp-89 mRNA rescues the hematopoietic, but not the vascular, phenotype in clo/ mutants. The placement of zbp-89 upstream of scl in the transcriptional hierarchy of hematopoiesis probably explains the hematopoietic defects seen in zbp-89 morphants. Loss- and gain-of-function studies in vertebrate models have shown that SCL is essential for hematopoietic development from FLK1+ hemangioblasts (Mikkola et al., 2003): Scl/ mouse embryos die at embryonic day 9.5 because of a complete absence of primitive (yolk sac) and denitive (bone

marrow) blood cells (Porcher et al., 1996; Robb and Begley, 1997; Robb et al., 1996; Shivdasani et al., 1995). SCL-depleted zebrash embryos are also defective in primitive and denitive hematopoiesis, much like the zbp-89 morphants, as a result of the loss of expression of gata1, pu.1 and runx1 (Patterson et al., 2005). SCL binds LMO2 directly, which bridges it to GATA1 and to E-proteins within a multicomponent complex that mediates the function of SCL in development of the denitive erythroid progenitors (Wadman et al., 1997). However, neither the DNA-binding nor the N-terminal transactivation domains of SCL are required for specication of hematopoietic cell fate from FLK1+ mesoderm progenitors (Porcher et al., 1999), thus reecting differences in the composition of the SCL complex. In support of this is the nding that, in the more primitive hematopoietic progenitors, GATA2 may replace GATA1 as a component of the SCL complex, which also contains SP1 (as has been observed in SCL-dependent activation of the c-kit promoter) (Lecuyer et al., 2002). These ndings are consistent with the defects in primitive and denitive hematopoiesis observed in gata2 null mice (Tsai et al., 1994), and with the known role of SP1 in hematopoiesis (Tenen et al., 1997). Interestingly, expression of gata2 and lmo2 is normal in SCL-depleted zebrash embryos, but is signicantly reduced in zbp-89 morphants, suggesting that the expression of these factors, in addition to SCL, is also regulated by ZBP-89 in early hematopoietic progenitors. ZBP-89 contains a DNA-binding domain, as well as a transactivation domain (Hasegawa et al., 1997; Passantino et al., 1998). It may thus act as a transcriptional activator of scl, and/or as a component of the multi-factorial SCL complex, thereby endowing it with a DNA-binding function. Gain-of-function experiments show that ZBP-89 acts as a negative regulator of angiogenesis both in vivo and in vitro. Although ZBP-89-depleted zebrash embryos displayed no

DEVELOPMENT

ZBP-89 regulates hematopoiesis and angiogenesis

RESEARCH ARTICLE 3649

Antona, V., Cammarata, G., De Gregorio, L., Dragani, T. A., Giallongo, A. and Feo, S. (1998). The gene encoding the transcriptional repressor BERF-1 maps to a region of conserved synteny on mouse chromosome 16 and human chromosome 3 and a related pseudogene maps to mouse chromosome 8. Cytogenet. Cell Genet. 83, 90-92. Bernstein, R., Bagg, A., Pinto, M., Lewis, D. and Mendelow, B. (1986). Chromosome 3q21 abnormalities associated with hyperactive thrombopoiesis in acute blastic transformation of chronic myeloid leukemia. Blood 68, 652-657. Bray, P., Lichter, P., Thiesen, H. J., Ward, D. C. and Dawid, I. B. (1991). Characterization and mapping of human genes encoding zinc nger proteins. Proc. Natl. Acad. Sci. USA 88, 9563-9567. Burns, C. E., DeBlasio, T., Zhou, Y., Zhang, J., Zon, L. and Nimer, S. D. (2002). Isolation and characterization of runxa and runxb, zebrash members of the runt family of transcriptional regulators. Exp. Hematol. 30, 1381-1389. Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. and Keller, G. (1998). A common precursor for hematopoietic and endothelial cells. Development 125, 725-732. Chung, Y. S., Zhang, W. J., Arentson, E., Kingsley, P. D., Palis, J. and Choi, K. (2002). Lineage analysis of the hemangioblast as dened by FLK1 and SCL expression. Development 129, 5511-5520. Cross, L. M., Cook, M. A., Lin, S., Chen, J. N. and Rubinstein, A. L. (2003). Rapid analysis of angiogenesis drugs in a live uorescent zebrash assay. Arterioscler. Thromb. Vasc. Biol. 23, 911-912. Davidson, A. J., Ernst, P., Wang, Y., Dekens, M. P., Kingsley, P. D., Palis, J., Korsmeyer, S. J., Daley, G. Q. and Zon, L. I. (2003). cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. Nature 425, 300-306. DSouza, S. L., Elefanty, A. G. and Keller, G. (2005). SCL/Tal-1 is essential for hematopoietic commitment of the hemangioblast but not for its development. Blood 105, 3862-3870. Fehling, H. J., Lacaud, G., Kubo, A., Kennedy, M., Robertson, S., Keller, G. and Kouskoff, V. (2003). Tracking mesoderm induction and its specication to the hemangioblast during embryonic stem cell differentiation. Development 130, 4217-4227. Feraud, O., Cao, Y. and Vittet, D. (2001). Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis. Lab. Invest. 81, 1669-1681. Fouquet, B., Weinstein, B. M., Serluca, F. C. and Fishman, M. C. (1997). Vessel patterning in the embryo of the zebrash: guidance by notochord. Dev. Biol. 183, 37-48. Gering, M., Rodaway, A. R., Gottgens, B., Patient, R. K. and Green, A. R. (1998). The SCL gene species haemangioblast development from early mesoderm. EMBO J. 17, 4029-4045. Gering, M., Yamada, Y., Rabbitts, T. H. and Patient, R. K. (2003). Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. Development 130, 6187-6199. Grutz, G. G., Bucher, K., Lavenir, I., Larson, T., Larson, R. and Rabbitts, T. H. (1998). The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specically in immature T cells. EMBO J. 17, 4594-4605. Hall, M. A., Curtis, D. J., Metcalf, D., Elefanty, A. G., Sourris, K., Robb, L., Gothert, J. R., Jane, S. M. and Begley, C. G. (2003). The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proc. Natl. Acad. Sci. USA 100, 992-997. Hasegawa, T., Takeuchi, A., Miyaishi, O., Isobe, K. and de Crombrugghe, B. (1997). Cloning and characterization of a transcription factor that binds to the proximal promoters of the two mouse type I collagen genes. J. Biol. Chem. 272, 4915-4923. Herbomel, P., Thisse, B. and Thisse, C. (1999). Ontogeny and behaviour of early macrophages in the zebrash embryo. Development 126, 3735-3745. Huber, T. L., Kouskoff, V., Fehling, H. J., Palis, J. and Keller, G. (2004). Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. Nature 432, 625-630. Kaczynski, J., Cook, T. and Urrutia, R. (2003). Sp1- and Kruppel-like transcription factors. Genome Biol. 4, 206. Kalev-Zylinska, M. L., Horseld, J. A., Flores, M. V., Postlethwait, J. H., Vitas, M. R., Baas, A. M., Crosier, P. S. and Crosier, K. E. (2002). Runx1 is required for zebrash blood and vessel development and expression of a human RUNX1CBF2T1 transgene advances a model for studies of leukemogenesis. Development 129, 2015-2030. Kennedy, M., Firpo, M., Choi, K., Wall, C., Robertson, S., Kabrun, N. and Keller, G. (1997). A common precursor for primitive erythropoiesis and denitive haematopoiesis. Nature 386, 488-493. Lacaud, G., Gore, L., Kennedy, M., Kouskoff, V., Kingsley, P., Hogan, C., Carlsson, L., Speck, N., Palis, J. and Keller, G. (2002). Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro. Blood 100, 458-466. Lahlil, R., Lecuyer, E., Herblot, S. and Hoang, T. (2004). SCL assembles a multifactorial complex that determines glycophorin A expression. Mol. Cell. Biol. 24, 1439-1452.

detectable defects in vasculogenesis, as reected by the normal expression of k1 and i1 markers, forced expression of ZBP-89 in zebrash lead to angiogenic remodeling defects, as reected by the impaired tie1 and k1 expression in the intersomitic (Fig. 5H,J) and axial blood vessels (Fig. 5L). Furthermore, ectopic expression of ZBP-89 in ESCs lead to defective sprouting angiogenesis and a reduction in the number of CD31+ and VE-Cadherin+ endothelial cells. By contrast, the late angiogenic remodeling in mice and the loss of k1 expression in the dorsal aorta in zebrash are both seen when SCL function is lost. One interpretation for these contrasting ndings is that ZBP-89 may act as a transcriptional repressor of SCL in FLK1+SCL angioblasts, where ZBP-89 is expressed, leading to the observed angiogenic defects. This scenario may explain the inability of overexpressed ZBP-89 to rescue the vascular phenotype in clo/ mutants, in contrast to SCL. Many transcription factors, including ZBP-89 (Merchant et al., 1996), SCL (Grutz et al., 1998; Lahlil et al., 2004) and GATA1 (Rodriguez et al., 2005) can function as activators or repressors, in part through the differential recruitment of co-activators and co-repressors depending on the cellular context. Alternatively, enforced expression of ZBP-89 in angioblasts might interfere with endogenous SCL complexes through sequestration, leading to the same phenotype that is produced by the loss of function of SCL. Because loss of ZBP-89 function is not associated with defects in vasculogenesis, its downregulation of SCL when overexpressed appears to be limited to the angiogenic phase of vascular development. Conditional loss of ZBP-89 function will help to distinguish between these possibilities. In addition to its role in hemangioblast fate commitment towards hematopoietic progenitors shown here, ZBP-89 may have additional roles at other branching points in the hematopoietic transcriptional hierarchy. Conditional knockout studies in mice have demonstrated that sustained scl expression is essential for hematopoietic differentiation towards the erythroid-megakaryocytic pathway (Hall et al., 2003; Mikkola et al., 2003; Sanchez et al., 2001). Whether ZBP-89 is involved in the sustained expression of scl, and/or participates in the function of the SCL complex at this stage, remains to be determined. In summary, our results suggest that ZBP-89 is a lineagedetermining transcription factor that not only activates hematopoietic lineage-specic genetic programs, but may also suppress endothelial cell differentiation. Its position upstream of SCL in the transcriptional hierarchy of hematopoiesis suggests that it may also be involved in some of the effects that SCL mediates in adult hematopoiesis.
We wish to thank Dr Shuo Lin for transgenic gata1:EGFP and fLk1:EGFP zebrash, Dr Kyunghee Choi for Scl-hCD4 ES cells, Dr En Li for J1 ES cells, Chengyan Wang for help on Fig. S2, Drs Leonard I. Zon, Kathryn Crosier, Roger Patient, Lisa A. Steiner, David G. Ransom and Bernard Thisse for probes, and Amy Ronco, Amy Doherty, Shannon Fishman and Humberto Urquiza of the Developmental Biology Lab at the Massachusetts General Hospital for collecting embryos. The genomic sequence used was produced by the Zebrash Sequencing Group at the Sanger Institute and can be obtained from ftp://ftp.ensembl.org/pub/traces/zebrash. This work was supported by grants from the National Institutes of Health and NIDDK. J.-W.X. is supported by grant AG19676 from NIH and C.S.S. is supported by grant-in-aid 0355696T from AHA. Supplementary material Supplementary material for this article is available at http://dev.biologists.org/cgi/content/full/133/18/3641/DC1 References Al-Adhami, M. A. and Kunz, Y. W. (1977). Ontogenesis of haematopoietic sites in brachydanio rerio. Dev. Growth Differ. 19, 171-179.

DEVELOPMENT

3650 RESEARCH ARTICLE

Lecuyer, E., Herblot, S., Saint-Denis, M., Martin, R., Begley, C. G., Porcher, C., Orkin, S. H. and Hoang, T. (2002). The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. Blood 100, 2430-2440. Liao, E. C., Paw, B. H., Oates, A. C., Pratt, S. J., Postlethwait, J. H. and Zon, L. I. (1998). SCL/Tal-1 transcription factor acts downstream of cloche to specify hematopoietic and vascular progenitors in zebrash. Genes Dev. 12, 621-626. Liao, W., Bisgrove, B. W., Sawyer, H., Hug, B., Bell, B., Peters, K., Grunwald, D. J. and Stainier, D. Y. (1997). The zebrash gene cloche acts upstream of a k-1 homologue to regulate endothelial cell differentiation. Development 124, 381-389. Long, Q., Meng, A., Wang, H., Jessen, J. R., Farrell, M. J. and Lin, S. (1997). GATA-1 expression pattern can be recapitulated in living transgenic zebrash using GFP reporter gene. Development 124, 4105-4111. Lyons, M. S., Bell, B., Stainier, D. and Peters, K. G. (1998). Isolation of the zebrash homologues for the tie-1 and tie-2 endothelium-specic receptor tyrosine kinases. Dev. Dyn. 212, 133-140. Merchant, J. L., Iyer, G. R., Taylor, B. R., Kitchen, J. R., Mortensen, E. R., Wang, Z., Flintoft, R. J., Michel, J. B. and Bassel-Duby, R. (1996). ZBP-89, a Kruppel-like zinc nger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol. Cell. Biol. 16, 6644-6653. Mikkola, H. K., Klintman, J., Yang, H., Hock, H., Schlaeger, T. M., Fujiwara, Y. and Orkin, S. H. (2003). Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 421, 547-551. Mucenski, M. L., McLain, K., Kier, A. B., Swerdlow, S. H., Schreiner, C. M., Miller, T. A., Pietryga, D. W., Scott, W. J., Jr and Potter, S. S. (1991). A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 65, 677-689. Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G. and Downing, J. R. (1996). AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321-330. Orkin, S. H. and Zon, L. I. (2002). Hematopoiesis and stem cells: plasticity versus developmental heterogeneity. Nat. Immunol. 3, 323-328. Palis, J., Robertson, S., Kennedy, M., Wall, C. and Keller, G. (1999). Development of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse. Development 126, 5073-5084. Park, C., Ma, Y. D. and Choi, K. (2005). Evidence for the hemangioblast. Exp. Hematol. 33, 965-970. Park, H., Shelley, C. S. and Arnaout, M. A. (2003). The zinc nger transcription factor ZBP-89 is a repressor of the human beta 2-integrin CD11b gene. Blood 101, 894-902. Passantino, R., Antona, V., Barbieri, G., Rubino, P., Melchionna, R., Cossu, G., Feo, S. and Giallongo, A. (1998). Negative regulation of beta enolase gene transcription in embryonic muscle is dependent upon a zinc nger factor that binds to the G-rich box within the muscle-specic enhancer. J. Biol. Chem. 273, 484-494. Patterson, L. J., Gering, M. and Patient, R. (2005). Scl is required for dorsal aorta as well as blood formation in zebrash embryos. Blood 105, 3502-3511. Pekarsky, Y., Zabarovsky, E., Kashuba, V., Drabkin, H., Sandberg, A. A., Morgan, R., Rynditch, A. and Gardiner, K. (1995). Cloning of breakpoints in 3q21 associated with hematologic malignancy. Cancer Genet. Cytogenet. 80, 18. Porcher, C., Swat, W., Rockwell, K., Fujiwara, Y., Alt, F. W. and Orkin, S. H. (1996). The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 86, 47-57. Porcher, C., Liao, E. C., Fujiwara, Y., Zon, L. I. and Orkin, S. H. (1999). Specication of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development 126, 46034615.

Development 133 (18)

Ransom, D. G., Bahary, N., Niss, K., Traver, D., Burns, C., Trede, N. S., PaffettLugassy, N., Saganic, W. J., Lim, C. A., Hersey, C. et al. (2004). The zebrash moonshine gene encodes transcriptional intermediary factor 1gamma, an essential regulator of hematopoiesis. PLoS Biol. 2, E237. Robb, L. and Begley, C. G. (1997). The SCL/TAL1 gene: roles in normal and malignant haematopoiesis. BioEssays 19, 607-613. Robb, L., Elwood, N. J., Elefanty, A. G., Kontgen, F., Li, R., Barnett, L. D. and Begley, C. G. (1996). The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J. 15, 4123-4129. Rodriguez, P., Bonte, E., Krijgsveld, J., Kolodziej, K. E., Guyot, B., Heck, A. J., Vyas, P., de Boer, E., Grosveld, F. and Strouboulis, J. (2005). GATA-1 forms distinct activating and repressive complexes in erythroid cells. EMBO J. 24, 23542366. Sanchez, M. J., Bockamp, E. O., Miller, J., Gambardella, L. and Green, A. R. (2001). Selective rescue of early haematopoietic progenitors in Scl(/) mice by expressing Scl under the control of a stem cell enhancer. Development 128, 4815-4827. Shivdasani, R. A., Mayer, E. L. and Orkin, S. H. (1995). Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 373, 432-434. Stainier, D. Y., Weinstein, B. M., Detrich, H. W., 3rd, Zon, L. I. and Fishman, M. C. (1995). Cloche, an early acting zebrash gene, is required by both the endothelial and hematopoietic lineages. Development 121, 3141-3150. Takeuchi, A., Mishina, Y., Miyaishi, O., Kojima, E., Hasegawa, T. and Isobe, K. (2003). Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis. Nat. Genet. 33, 172-176. Tenen, D. G., Hromas, R., Licht, J. D. and Zhang, D. E. (1997). Transcription factors, normal myeloid development, and leukemia. Blood 90, 489-519. Thompson, M. A., Ransom, D. G., Pratt, S. J., MacLennan, H., Kieran, M. W., Detrich, H. W., 3rd, Vail, B., Huber, T. L., Paw, B., Brownlie, A. J. et al. (1998). The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. Dev. Biol. 197, 248-269. Tsai, F. Y., Keller, G., Kuo, F. C., Weiss, M., Chen, J., Rosenblatt, M., Alt, F. W. and Orkin, S. H. (1994). An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371, 221-226. Visvader, J. E., Fujiwara, Y. and Orkin, S. H. (1998). Unsuspected role for the Tcell leukemia protein SCL/tal-1 in vascular development. Genes Dev. 12, 473479. Wadman, I. A., Osada, H., Grutz, G. G., Agulnick, A. D., Westphal, H., Forster, A. and Rabbitts, T. H. (1997). The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 16, 3145-3157. Wang, Z., Cohen, K., Shao, Y., Mole, P., Dombkowski, D. and Scadden, D. T. (2004). Ephrin receptor, EphB4, regulates ES cell differentiation of primitive mammalian hemangioblasts, blood, cardiomyocytes, and blood vessels. Blood 103, 100-109. Weinstein, B. M., Schier, A. F., Abdelilah, S., Malicki, J., Solnica-Krezel, L., Stemple, D. L., Stainier, D. Y., Zwartkruis, F., Driever, W. and Fishman, M. C. (1996). Hematopoietic mutations in the zebrash. Development 123, 303309. Westereld, M. (1993). The Zebrash Book: A Guide for the Laboratory use of Zebrash (Brachydanio rerio). Eugene, OR: University of Oregon Press. Willey, S., Ayuso-Sacido, A., Zhang, H., Fraser, S. T., Sahr, K. E., Adlam, M. J., Kyba, M., Daley, G. Q., Keller, G. and Baron, M. H. (2006). Acceleration of mesoderm development and expansion of hematopoietic progenitors in differentiating ES cells by the mouse Mix-like homeodomain transcription factor. Blood 107, 3122-3130. Yamagata, N., Shimazaki, C., Kikuta, T., Hirai, H., Sumikuma, T., Sudo, Y., Ashihara, E., Goto, H., Inaba, T., Fujita, N. et al. (1997). A translocation between 3q21 and 12q24 in a patient with minimally differentiated acute myeloid leukemia (AML-M0). Cancer Genet. Cytogenet. 97, 90-93.

DEVELOPMENT